Ultragenyx Pharmaceutical Inc. (RARE)
After hours:
- Simply Wall St.
Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders have endured a 51% loss from investing in the stock a year ago
Taking the occasional loss comes part and parcel with investing on the stock market. And there's no doubt that...
- GlobeNewswire
Ultragenyx to Present at Goldman Sachs Global Healthcare Conference
NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, and Mardi Dier, the company’s Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Thursday, June 16, 2022, at 10:00
- GlobeNewswire
Ultragenyx to Present at Jefferies Global Healthcare Conference
NOVATO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President, will present at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 2:30 PM ET in New York. The live and archived webcast of the pre
